Neuropathic pain represents a multifaceted and often incapacitating condition arising from damage or dysfunction within the nervous system. Unlike nociceptive pain, which stems from tissue injury or inflammation, neuropathic pain involves aberrant signaling within the nervous system itself. This dysfunctional signaling can occur at various levels, ranging from peripheral nerves to the spinal cord and brain. Common causes of neuropathic pain include diabetic neuropathy, postherpetic neuralgia (associated with shingles), spinal cord injury, and nerve compression syndromes like carpal tunnel syndrome. The symptoms of neuropathic pain are diverse but frequently include sensations such as burning, shooting, or electric shock-like feelings, along with heightened sensitivity to touch or temperature changes in the affected area. Managing neuropathic pain poses significant challenges and often necessitates a multidisciplinary approach. Medications such as antidepressants, anticonvulsants, and opioid analgesics may be prescribed to modulate abnormal nerve signaling and alleviate pain. Additionally, interventions such as nerve blocks, spinal cord stimulation, and physical therapy can play a crucial role in symptom management and enhancing the quality of life for individuals afflicted with neuropathic pain. The complexity of neuropathic pain underscores the importance of continued research efforts aimed at unraveling its underlying mechanisms and developing more effective treatment strategies to alleviate suffering and improve outcomes for those affected by this debilitating condition.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States